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formed remotely using vendor-specific hardware and softwara. In this study,
we examined the technical feasibility of displaying diagnostic quality images
on a remote site PC with an Internet WEB browaer (Netscape 2.02). Blinded
review of 26 consecutive studies establishad an interpretive concordance of
83% for any abnormality, 81Y0for multivesael ischemia, and 85% forterrftoty
of abnormality when compared with images read from films. Technical issuea
involved were: 1) Development of a display format for presentation of axial
slices, polar maps with quantitative information, and planar imageson a 1020
x 620, 6 bit display; 2) Security of the WEB aite; 3) Image conversion from
raw data to 6 bit grey scale (GIF image format); 4) Average download time of
104 + 6 seconds using a 26.6 kbs modem with V34 compression; 5) Display
on a Pentium 100 with a 1 Mb video card; 6) Video card display settings of 8
bit color and 600 x 600 resolution. Image quality scored by two independent,
expati obsewere on a scale of 1-5 (1 = inadequate; 2 = poor; 3 = adequate;
4 = good; 5 = auperfor) ranged from 3 to 4 (average value = 3.7).
Corrc/usion:This investigation establishes the technical feeeibilityof inter-
pretation of images over the Internet using a PC and a WEB browser. While
the current configuration permits reasonably high interpretive concordance
relative to traditional films, incorporation of additional data (such as rotating
projection images and pertinent aspects of a patient’s history) and a higher
quality image display medium may further improve results.
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m1074118 Design, Synthesis snd In Vivo Actions of a Novel
Chimeric Peptide to B-Type (BNP) and C-Type
(CNP) Natriuretic Peptidea
W.L. Chau, M. Jougaaaki, C.-M. Wei, J.C. Burnett, Jr.. Mayo Clinic,
Rochestec MN, USA
CNP,a member of the natriuretic peptide system (NPS) of endothelial origin,
is a potent venodilator with minimal natriuretic actions. CNP exerts vascular
actions via generation of cGMP after binding to the NPR-B receptor. BNP,
a member of the NPS of myocardial origin, is the most potent natrfuretic
peptide. BNP mediates its natriuretic effect via the NPR-A receptor. Both
CNP and BNP posaeae a 17-amino acid ring structura, but BNP has a 6-
amino acid COOH-terminus which CNP Iacka. This atudy was undertaken
to investigate the in vivo actions of a novel 26-amino acid chimeric paptide
termed “CB-NP”. This peptide possesses the 22-amino acid structure of
CNP and the 6-amino acid COOH terminus of BNP.CB-NP was synthesized
uaing FLMC chemistry on a peptide synthesizer and purified by reverse
phase HPLC. In 5 anesthetized dogs, cardiorenal function was measured
in reaponse to CB-NP (50 ngkdmin IV) followed by co-infusion of HS-142-
1, a dual inhibitor of NPR-A and B receptors (3 mglkg IV bolua). CB-NP
decreased right atrlal pressure (-1.2+ 0.3 to –2.2 + 0.4 mmHg, p < 0.05)
and cardiac output (3.6 + 0.2 to 3.1 + 0.3 l/rein, p < 0.05) consistent with
a decrease cardiac preload. HS-142-1 did not reverae these effects. CB-NP
wee marfradly natriuretic with increaaea in glomerular filtration rate (38 + 4
to 52 & 5 ml/min, p < 0.05), urinary sodium excretion (65&24 to 240 +76
mEq/min, p < 0.05), fractional sodium excretion (1.1 + 0.4 to 3.3 + 1.O%,p
< 0.05) and a decrease in distal fractional reabsorption of sodium (96.4 +
1.0 to 91.2+ 1.8Y0,p < 0.05). CB-NP increaaed plasma cGMP (3.1 + 0.9 to
7.1 +2.8 pmol/ml, p e 0.05) and urinary cGMP excretion (733 + 124to 1843
+ 356 pmol/ml, p -=0.05). HS-142-I abolished all these effects. The current
study suggeats that CB-NP poaseases the venodilating actions of CNP and
the natrfuretic actions of BNP which are secondary to unique co-activation
of both NPR-A and B receptors. This unique paptide may have therapeutic
potential in cardiorenal disease statea.
j 1074-119] CcrrttrolofCardiac HypertrofIhyanci Natrluretic
Peptide Production by Endogenoua Angiotensin
II in Experimental Hqart Feilure
J.A. Grantham, D.D. Borgeaon, T.L. Stevens, M.M. Redfiald, J.C. Burnett,
Jr.. Mayo Clinic, Rochastec MN, USA
Angiotenain II (ANG H)induces cell hypertrophy and natriuratic peptide (NP)
production supporting a role for atrial (ANP) and brain (BNP) natriuretic
paptidea as serum markers for left ventricular hypartrophy (LVH). The effect
of chronic ACE inhibition (ACEI) in congestive hearl failure (CHF) upon LVH
and plasma NPa remaina poorly defined. We tested the hypothesis that
inhibition of ANG II with ACEI during the progression of CHF would prevent
LVHand attenuate increases in circulating ANP and BNP,and that these NPs
would be powerful serum markers for LVHwith and without ACEI during CHF.
CHF wee produ@ by rapid ventricular pacing in the preaence (n = 6, CHF+
ACEI) andabaence (n =6, CHF) of enalapril (10 mg PObid). Plasma NPsand
ANG IIwera determined during the progression of CHF. Left ventricular mass
index (LVMI) was determined at autopsy. ACEI prevented the late incraase
in ANG II eeaociated with CHF (A 10 + 3 vs 143 + 67, P < 0.05), and
attenuated the increase in ANP and BNP during the progression of CHF.
without differences in cardiac filling pressures. * denotes p <0.05 vs CHF
CHF CHF + ACEI
BL Early Late BL Early Late
ANP (p@ml) 43i 11 233+ 64 416&93 50+10 140* 41 235& 39*
BNP (pg/ml) 19+6 77 l 2O 155+ 32 20+6 20* 7* 54* 7*
ACEI preventad the increase in LVMI (4.2 + 0.1 VS4.9 + 0.2 m~kg TBW,
p < 0.05) and ANP and BNP correlated with LVMI (r= 0.65, p <0.01 and
r = 0.87, p <0.001, respectively). We conclude that endogenous ANG II
modulates LVH and the activation of circulating NPs in experimental CHF.
Additionally, ACEI prevents LVH and activation NPs in experimental CHF,
and both ANP and BNP are powerful markera of LVH in the presence and
absence of ACEI.
1074-120 Quantitative Expression of the Tissue Renin
Angiotensin System in Left Ventricles with
Aofiic Stenosis Compared to Normal Hearta
1.Haehnel, L. Goadel-Meinen, F.-J.Neumann, M. Homann, H. Meisner,
A. Sch6mig. Deutsches Herzzentrum and 1.Med. Klinik, Klinikum rechts
derlaac TachnischeUniverait#, Munich, Germany
Angiotensin II is a potent growth factor in cardiovascular tissues. It’s local
effects are determined by the supply with angiotensinogen, which is con-
verted via ACE and chymase to the biological active compeund. Moat of it’s
known effects are mediated by tha AT1-receptor.The AT2-receptor is mainly
expressed in fetal tissues and wound haaling, indicating It’apredominant role
in growth, development and differentiation.
We investigated the expression of the tisaue renin angiotenein system
(tissue RAS) intissuesamples from Ieftventriciea with aorticstenosis (n = 12)
COMpSrSdto frOMMlleftventricles from not transplantad donor hearts (n = 6)
by quantitative reverse transcription-polymersae chain reaction (RT-PCR).
Recently, we described the construction of a multistendard cRNA, which
enables the quantification of the gene expression of the different components
of the human tissue RAS by coamplification with specific oligonucleotide
primers.
Resu/ts: the AT1-receptor expression decreased markedly in left ventri-
cles with aortic stenosia (p < 0.01), while there was no aignificsnt difference
in the AT2-racaptor expression. The angiotensinogen expression is signifi-
cantly enhanced compared to normal hearts. No aignificent differenoea were
found in the expression of ACE and chymaae.
Conclusion: The study revealed a different regulation of the AT-reoeptor
subtypes in left ventricular hypertrophy caused by aortic stenosis, which
is associated by an enhanced expression of the angiotensin II precursor
angiotensinogen.
[1074-121 \ Strong poaitiveandNegative cis-acting
Elaments Control Endothelin B Receptor
Expression
J.C. Monge, J. Zhang, P.J.W.Smith, A. Srivasteva. Universifyof Toronto,
Toronto,Drrtarfo,Canada
The Endothelin B receptor (ETs) isexpreas6d in neural and endothelial cells.
It playsan important role inthedevelopment of theneursd crest and isooupled
to the production of factors involved in normal endothelial’functions such as
nitric oxide. Its absence or downregulation likely plays a key role in the
development of pulmonaty hypertension and other instances of endothelial
dysfunction. To understand ikaregulation, we obtained mouse ETB genomic
clones and characterized a 1.6 kb fragment that contained all of exon I -
including 0.2 kb of 5’ untranslated region (UTR)- and approximately 0.66 kb
of the 5’ flanking region. The transcription initiation site is located at –200
relativa to the translational atart site. Transfaotion experiments showed that
this fragment functioned as a specific promoter of a Iuciferase reporter gene
in P19 neural cells expressing ETs. Serial deletions between –660 to –160
led to a > 12-fold increase in Iucifersse activity. The deletion of -160 to –75
(including a 40 bp long region of 83% homology between the mouse and
tha human genes) resulted in a 95% loss of activity of the reporter gene. In
conclusion: 1)strong silencer elements are present in the 5’ flanking region of
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the ETBgene, 2) A highly conserved region in its 5’UTR harbors an element
responsible for high level expression of a reporter gene in cells expressing
ETB.These elements may help us understand ETB regulation during neural
crest development and in conditions associated with endothelial dysfunction
auch as heart failure, pulmonaty hypetiension and atherosclerosis.
m1074122 Aldosterone synthese gene polymorphism
medicts left ventricular size end function in
pereons free of heert dieeese
A. Hautanen, M. Kupari, P.Koskinen, J. Virolainen, H. Nikkil~, L. Lankinen,
P.C.White. Department of Medicine, University of Helsinki, Finland,
Department of Pediatrics, Univeraityof TexasSouthwestern Medical Center,
Dallas, TX, USA
Aldosterone has many effects on heart and circulation. Genetic variation in
aldoaterone synthesis could therefore have esrdiac implications. Aldosterone
synthase (CYPI1 B2) catalyzes the last steps of aldosterone formation. We
atudiad whether CYPIIB2 gene .polymorphism predicts left ventricular (LV)
size, mass or function in humans.
84 persons (40 men) free of heart disease born in 1954 were studied by
M-mode and Doppler eehocardi09raPhYand genotyped by polymerasechain
reaetion for –344 cytosinehhymidine (C/T) polymorphism in the promoter of
the CYPll B2gene. The LVmeasurements (mean *SD) bythe CrTgenotypS
group were as follows:
Measurement -3441T n. 22 –344CTn=42 –244CCn= 20 P(anova)
EDD,mm 47* 3 50*4 51l 4 0.002
ESD,mm 31+3 34*4 35+6 0.013
Mass,g 149*39 169+46 182+58 0.0B2
EIA 1.7* 0.3 1.5+ 0.3 1.6+ 0.3 0.024
AFF,‘h 23+ 6 27* 6 26+6 0,004
EDD = end-diastolic diameter; ESD = end-systolic diameter; E/A= trans-
mittal earfy/atrial velocity ratio; AFF = atrial filling fraction. The influence of
CYPIIB2 genotype on LV measurements was independent of sex, body
size, blood pressure and salt intake.
We conclude that DNA polymorphism in the CYP11B2 gene predicts LV
structure and function in persons free of heart disease.
m1074123 Effect of Estrogen on Protein and DNASynthesie and Estrogen Receptor Statua in
Cerdiac Fibroblasts
A.V. Sigel, G.A.J. Riegger, H. Schunkert. Depaflnrent ofkrtefnal &fedicin //,
Universifyof Regerwtwrg, Germany
Estrogen exerta a clinically relevant anti-atherogenic effect in women. In ad-
dition, eetrogen may bind to receptors on vascular smooth muscle cells and
modulate the growth of these cells. Little, however, is known about its direct
effects on cardiac fibroblasts, which are responsible for exfraeellular matrix
production in the heart. We, therefore, investigated the role of estrogen on
male adult rabbit cardiac fibroblasts, which were grown until subeonfluent
in DMEM supplemented with IOYOFBS. Western immuno slot blot analysis
demonstrated that eardiacfibroblast.sexpress estrogen reeaptorprotein. The
density of the eetrogen receptor significantly increased with the degree of
conflueney from 24 through 120 houra in culture (685%, p = 0.005). Next, we
investigated theeffectcIf estro9en on DNAsynthesis measuring 3H-thymidine
incorporation. Estrogen dose-dependently decreased DNA synthesis of car-
diac fibroblasts. The maximum decrease was observed with 10 nM estrogen
(78%, p =0.0005). In addition, estrogen treatment decreased protein synthe-
sis, as measured by 3H-phenylalanine incorporation by 64% (p < O.O@I). In
contrast, transforming growth factor bata 1 (TGF-fJI) protein concentrations
increased by 178% (p < 0.05). Furthermore, treatment with 10 nM, 500 nM,
and 10 r.tMexogenous estrogen further increased estrogen receptor protein
immunoreaetivity by 13°A (p < 0.0005), 17% (p < 0.005), and 16% (p <
0.005), respectively. We, therefore, conclude that estrogens modulate pro-
tein and DNAsyiitheais in cardiac fibroblasts. The anti-proliferative effa@ of
estrogen may involve the induction of TGF-BI and/or a positive feedback on
the expression of its receptor.
m1074124 Interaction Between Estradiol and MechanicalStrain in Human Vasculer Smooth Muecle Cells
unknown. A direct inhibitoy effect on vascular smooth muscle growth has
been proposed, but conflicting data exist, ahowing stimulation of mitogenesis
under some circumstances. We examined the effect of different concentra-
tions of 17@-estradiolon mitogenesis induced by cyclic mechanical strain in
human vascular smooth muscle cells in culture. Cells were grown to con-
fluence on fibronectin-coated plates with silicone-elastomer bottoms. They
were then expoeed to cyclic mechanical strain (60 cyclea/min, 46 h), in the
presence and absence of 17@-estradiol(1 nM or 1 vM). 3H-Thymidine was
measured during the last six hours. Cyclic mechanical strain induced 1.5 to
2 fold increasee in DNA syntheeis. While estradiol, 1 nM caused an inhibi-
tion of strain-induced mitogenesis, estradiol 1 KM caused an enhancement.
Thymidine incorporation data (cpmJwell)are shown below.
Control 3e34& 386
Strain 6753 & 386
Strain+ Estradiol1 nM 3397*465
Strain+ Estradiol1 WM S875 & 515
The extent of inhibition of strain-induced mitogenesis by physiological
concentrations of estradiol (1 nM) was attenuated by the estrogen receptor
antagonist ICI 182,780 (1 nM). We conclude that estrogen, in physiological
concentrations, inhibits strain-induced mitogenesis via an estrogen-receptor
mediated process, and in supraphysiological concentrations, stimulates mi-
togenesis, probably via non-specific steroid effects. Our observations may
have implications for the cardiovascular benefits of low dose eetrogens and
the risks associated with high dose estrogens seen in epidemiological stud-
ies.
m1074125 Proteinaae Activated Receptor-2(PAR-2)-Mediated Mitogenic Responeea Are
Induced By Human Mast Cell Tryptases
H. Mirza, V. Schmidt, J. Jesty, W.F.Bahou. State Univeraityof New Yorkat
Stony Brook, USA
PAR-2 is the second proteolytically activated receptor that mediates cell
activation events by receptor cleavage. PAR-2 is expreseed on vaacular
endothelial cells and is functionally coupled to the thrombin receptor (TR)
in vitro. To further study previously identified mitogenic effects of PAR-2,
we utilized the IL-3-dependent murine Iymphoid cell line BaF3 to gener-
ate a stable cell line expressing PAR-2 (BaF3/PAR-2). Both wild-type BaF3
and BaF3/PAR-2cells demonstrated proliferative responsea when incubated
with! 10%WEHI media (as the source of IL-3), as evaluated by MTT asaay..ln
contrast, only BaF3/PAR-2 cells exhibitad mitogenic responses when grown
in IL-3-deficient media supplemented with PAR-2 activating peptide (SLl-
GRL, PARW-U). No responses were evident in BaF3/PAR-2 cells using the
inactive peptide LSIGRL. Xenopus oocytes microinjectad with PAR-2 cRNA
demonstrated a dose-dependent responsiveness to the thrombin receptor
activating peptide (TR@-47SFLLRN), and incubation of BaF3/PAR-2 cella
with 100 KM TR42–-47for 46 houre reproduced the proliferative response,
although at -75Y0 of that identified using equimolar PARW––W. Because
tryptase shares -70% homology with trypsin (previously shown to activate
PAR-2), we evaluated whether expressed forms of a- and p-tryptaee could
induce proliferative responses in BaF3/PAR-2 cells. Transient tranefaetion of
COS-I cells with human mast cell a- and @-ttyptasecDNA’s demonstrated
tryptase expression in supematants and cells extracts for both forms, aa
evaluated by quantitative radioimmunoassay. Comparable proliferative r-
sponses were evident using conditioned media from either a- or &tryptaae
expressad forms, whereas such responses were limited to wttyptase cell ex-
tracts only. These results identify mast cell tryptases as physiological serine
proteaee agonists for PAR-2 with implications for elucidating the molec-
ular mechanisms regulating cell activation events mediated by proteases
generatad at the cell-surface during inflammatory, fibrinolytic or thrombosia-
regulated pathways.
in Culture
K. Sudhir, S. Ling, T.M. Chou, H.E. Ives, K. Chatterjae. Universifyof
California, San Francisco, CA, USA
The cellular basis of the eardioprotective effects of estrogen are largely
